Targeting non-coding RNAs to overcome cancer therapy resistance.

Chen B, Dragomir MP, Yang C, Li Q, Horst D, Calin GA. · 2022

Read Targeting non-coding RNAs to overcome cancer therapy resistance. by Chen B, Dragomir MP, Yang C, Li Q, Horst D, Calin GA. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9008121.txt.

Introduction

Chen and co-authors review how non-coding RNAs drive cancer drug resistance, and how to target them. Most RNA in cells never becomes protein. Three non-coding kinds run much of cancer's control wiring. Micro, long, and circular RNAs all feature. They steer growth, death, spread, and genome steadiness. They also rewire the paths that drugs attack. Resistance to all four therapy kinds traces back to them. Chemo, radiation, targeted drugs, and immune therapy all suffer.

The review maps resistance routes by RNA kind. It then treats the RNAs as warning markers. Some flag resistance before treatment starts. Others reveal it as it forms. Targeting the RNAs themselves is the hopeful turn. Delivery is the hard part of that plan. The authors weigh carrier options frankly. The field's promise and its bottlenecks share the page.

Catalog record

CREATORChen B, Dragomir MP, Yang C, Li Q, Horst D, Calin GA.
YEAR2022
COLLECTIONPAPERS
FORMATTXT
FILE SIZE122 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC9008121

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Targeting non-coding RNAs to overcome cancer therapy resistance By BaoQing Chen, Mihnea P. Dragomir, Chen Yang, Qiaoqiao Li, David Horst, George A. Calin Published in: Signal Transduction and Targeted Therapy DOI: 10.1038/s41392-022-00975-3 ABSTRACT It is now well known that non-coding RNAs (ncRNAs), rather than protein-coding transcripts, are the preponderant RNA transcripts. NcRNAs, particularly microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), are widely appreciated as pervasive regulators of multiple cancer hallmarks such as proliferation, apoptosis, invasion, metastasis, and genomic instability. Despite recent discoveries in cancer therapy, resistance to chemotherapy, radiotherapy, targeted therapy, and immunotherapy continue to be a major setback. Recent studies have shown that ncRNAs also play a major role in resistance to different cancer therapies by rewiring essential signaling pathways. In this review, we present the intricate mechanisms through which dysregulated ncRNAs control resistance to the four major types of cancer therapies. We will focus on the current clinical implications of ncRNAs as biomarkers to predict treatment response (intrinsic resistance) and to detect resistance to therapy after the start of treatment (acquired resistance). Furthermore, we will present the potential of targeting ncRNA to overcome cancer treatment resistance, and we will discuss the challenges of ncRNA-targeted therapy—especially the development of delivery systems. INTRODUCTION - OVERVIEW OF NCRNAS The cataloging of the non-coding RNA (ncRNA) world is constantly and dramatically changing. Recent findings underscore the fact that a number of ncRNA transcripts can code for micropeptides (of less than 100 amino acids) that play functional roles in normal and pathological processes, including cancer.1 These novel data show that at least some ncRNAs have either both functional coding and non-coding capabilities or are, in fact, coding transcripts for non-classic peptides. Hence, we are facing the question of what ncRNA means. Currently, the most studied types of “classic ncRNAs” are microRNAs (miRNAs),2 long-non-coding RNAs (lncRNAs),3 and circular RNAs (circRNAs).4 MiRNAs are short RNAs that originate from longer stem-loop structures and can bind and inhibit mRNAs.5 The biogenesis of miRNAs is a multistep process. MiRNAs are transcribed as primary miRNAs (pri-miRNAs) and processed in the nucleus by Drosha and Dgcr8 into precursor miRNAs (pre-miRNAs). After they are exported to the cytoplasm, pre-miRNAs are cleaved to form an miRNA/miRNA duplex. Only one of the two miRNAs formed will exert its inhibitory function, the other one being degraded.6 Several other unconventional miRNA functions have been reported, including binding and inhibiting proteins, activating Toll-like receptors, coding for peptides, activating the translation of mRNAs, inhibiting mitochondrial transcripts, triggering transcription, and inhibiting nuclear ncRNAs,7 making miRNAs complex and versatile molecules (Fig. 1a). The total number of known human miRNAs is in continuous expansion and currently includes 1917 precursors and 2654 mature molecules (miRBase, release 22.1).8 Many additional miRNAs, mostly with tissue-specific distribution, have also been discovered.9 Most of these genes are conserved between species.10Fig. 1Biogenesis and function of miRNAs, lncRNAs and circRNAs. a MIRNAs are transcribed as primary miRNAs (pri-miRNAs) that contain the characteristic stem-loop structure. Pri-miRNAs are processed in the nucleus by Drosha and DGCR8 and transformed into precursor miRNAs (pre-miRNAs). Pre-miRNAs are transported from the nucleus to the cytoplasm via Exportin 5 and then are turned into an miRNA duplex after being cleaved by Dicer. One strand of the miRNA duplex is incorporated as part of the miRNA-induced silencing complex (RISC), and the second strand is degraded. By base-pairings between miRNAs and their target mRNA, the RISC binds an mRNA and suppresses its translation or induces its degradation. Additionally, there are unconventional/atypical miRNA functions such as activating Toll-like receptors (TLRs), binding non-AGO proteins, binding other ncRNAs (sponging), and regulating transcription. b Most lncRNAs have a biogenesis similar to mRNAs (although several exceptions exist), being capped, spliced, and adenylated. The mature lncRNAs adopt complex 3D structures that give them their multivalent functions. The function of lncRNAs can be divided according to their cellular localization: bound to chromatin (often cis functions), intranuclear (usually trans functions), and intracytoplasmic (trans functions). LncRNAs bound to chromatin usually function as regulators of transcription and induce chromosome looping and histone modifications. Nuclear lncRNAs can assemble paraspeckles and interact with nuclear proteins. Cytoplasmic lncRNAs bind mRNAs and act as decoys, guides, and scaffolds to transcriptionally or post-transcriptionally regulate downstream target genes, bind proteins to modify their function and stability, code for micropeptides that are being translated, and bind other ncRNA species (including miRNAs). c CircRNAs have multiple biogenesis mechanisms, but a common event for all is back-splicing. Back-splicing can be induced by protein dimerization, sequence complementarity of flanking introns, exon skipping mechanisms, and intron lariat debranching. After forming an uninterrupted RNA loop, the transcript is exported into the cytoplasm, where it serves as an miRNA sponge that inhibits miRNAs to regulate the expression of target genes, as a decoy of RNA-binding proteins to modulate gene expression or translation, or as a platform for protein-protein interaction; additionally, these transcripts also can be translated into micropeptides. As observed, there is direct crosstalk between lncRNAs and miRNAs and between circRNAs and miRNAs via sponging, creating a network of ncRNA molecules. MiRNAs’ role in cancer was revealed in 2002, when it was discovered that in chronic lymphocytic leukemia (CLL) MIR15 and MIR16 are frequently deleted and their transcripts downregulated.11 Currently, miRNAs have been reported to be dysregulated in each type of investigated cancer.12–14 The complexity of miRNAs’ mechanisms of action and the multitude of targets has made it difficult for researchers to translate their findings into clinical practice,15 and a better understanding of their role in oncology is necessary. LncRNAs are by far the most complex type of ncRNAs, being arbitrarily defined as RNA molecules over 200 nucleotides long that are usually not translated into proteins. This definition is unfortunately vague. For example, because of their length, several primary miRNAs are considered to be lncRNAs if they have a function on their own, and of all ncRNAs, lncRNAs have the highest potential of coding peptides (this has been confirmed several times).1 The biogenesis of lncRNAs is similar to that of mRNAs, many of them being spliced, capped, and poly-adenylated. The complexity of these transcripts comes from their multifaceted 3D structure, which rapidly changes and gives them the ability to perform multiple functions.16,17 LncRNAs have cis (performed in the proximity of their transcription site) and trans (performed distant from the transcription site) functions.18 Typical cis functions are related to DNA transcription, chromatin modifications, and chromosomal looping. Well-defined trans functions include binding to mRNAs and changing their stability, binding to proteins and altering their function, interacting with other ncRNAs, and facilitating the assembly of paraspeckles19,20 (Fig. 1b). The research on lncRNA surged after the 2003 discovery of MALAT1’s involvement in the metastasis of non-small cell lung cancer (NSCLC).21 Similar to miRNAs, lncRNAs’ role in cancer is now well studied but only rarely translated into clinical practice, the exception being PCA3 as a biomarker for prostate cancer.22 A complementary approach is to classify lncRNA from a phylogenetic standpoint. LncRNAs can be transcripts of ultraconserved elements that are identical in mice, rats, and humans.23 These lncRNAs are named transcribed-ultraconserved regions and because of their high degree of conservation are expected to have essential functions.24 On the other hand, are the more recently emerged transcripts, the primate-specific lncRNAs, which often contain

Read the complete text